I hold a PhD in the field of epidemiology a masters degree in public health. My undergraduate training is in policy, economics and the sciences. I have utilized my training in employment with government, academia, private industry and to further analyze the fundamentals and technicals of all manner of companies in different sectors. Specifically, I like to trade growth companies, REITS, biotechnology/ pharmaceuticals, precious metals, blue chips and small-cap companies.
Each market day I get up at 530 am and begin working/analyzing data before my day job. I focus much on current events, earnings, and developments. I also work after market hours to cover after hours developments or interesting action during the day. I aim to conduct 2 analysis per business day, which helps me stay focused on my own finances.
I have been investing for about 10 years. I also enjoy trading short expiration options, and investing in stocks with 3-20 year horizons. I enjoy writing with Seeking Alpha to share my opinion and analyses. I am a large believer in the crowd source model championed by Seeking Alpha and believe every ounce of analysis and opinion should be considered when you invest your personal finances.
VFC is just a guy with an opinion. VFC's Stock House brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - the biotech, pharmaceutical and healthcare sectors. VFC's Stock House provides research, informational and opinion-based coverage of various companies and stocks in multiple sectors.
The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies. Do not Buy/Sell based solely on VFC's ideas or opinions.
The goal of VFC's Stock House is to 'call it like I see it' - while bringing new ideas, companies, and discussions to the eyes of investors and readers. This is supposed to be fun and new investors should not invest with the idea that this will 'pay the bills' or with the belief that a stock will just keep going up. DD is paramount, but so is sticking to pre-conceived entry and exit strategies and not letting emotional trading get in the way.
Goals must be realistic, if it sounds far fetched, then it probably is. Let the big boys eat the cake - the small investor is just trying to pick up some crumbs, and there's nothing wrong with that!
Renee Ann Butler is a freelance finance writer and former management consultant with over 15 years of experience in business management and strategy. She earned an MBA in financial management from Exeter in 2007 and has enjoyed a variety of international business experiences, working primarily with companies in England and Australia. Butler's work is centered on retail stocks and consumer trends. Her writing has appeared on TheStreet, Marketwatch, Insider Monkey, Seeking Alpha and Motley Fool.
Saj Karsan founded an investment and research firm that is based on the principles of value investing. He has an MBA from the Richard Ivey School of Business, has completed all three CFA exams, and has an engineering degree from McGill University. Visit his blog, Barel Karsan (http://barelkarsan.com/).
Alan Brochstein, CFA, was the first investment professional to devote himself to sharing his observations about the cannabis industry from an investor's perspective publicly. He runs 420 Investor, a subscription-based due diligence platform for investors interested in the publicly-traded cannabis stocks and is also the founder of New Cannabis Ventures, a content aggregation site focused on investors and entrepreneurs in the cannabis industry.
Alan has worked in the securities industry since 1986, primarily with the responsibility for managing investments in institutional environments until he founded AB Analytical Services in 2007 in order to provide independent research and consulting to registered investment advisors. In addition to advising several different hedge funds and investment managers, including Friedberg Investment Management, where he participated as a member of its investment management committee, Alan was also a senior analyst for the independent research firm Management CV. In 2008, he began providing a first-of-its-kind subscription-based service for individual investors, Invest By Model, which offered two different portfolios that investors could replicate in their own accounts for $20 per month. Alan also offered The Analytical Trader at Marketfy, where he used fundamental and technical analysis in a disciplined process to offer specific trade ideas geared towards swing traders.
Alan launched www.420Investor.com in late 2013 as the premier source of information for "Green Rush" investors seeking to capitalize on the proliferation of legalized medical and recreational cannabis. In March 2014, Alan, who is a member of the National Cannabis Industry Association, began to focus solely on the cannabis sector. He launched www.NewCannabisVentures.com in late 2015.
You can follow Alan on Facebook (www.facebook.com/420investor) or on Twitter (https://twitter.com/Invest420). Alan also moderates a large LinkedIn group focused on the cannabis industry, Cannabis Investors & Entrepreneurs (https://www.linkedin.com/groups/6523904)
I have been an independent investor and trader in the Forex, Stock Market, and Commodity markets for 10 years. I also serve as the managing director of a charitable fund.
Follow me on Twitter @spollack10
Eugene Eliot Narrett was born on December 27, 1948. He died on the night of December 6, 2013. Having just left an art gallery in Brattleboro, Vermont, where his paintings were on display, he crossed Union Street and was struck by a hit and run driver.
Professor Narrett was the first of five sons born to Dr. Sidney S. Narrett and Mrs. Beatrice Narrett.
Professor Narrett grew up in Passaic and Clifton, New Jersey. In 1963, at the age of fifteen, he won the Quality of Latin Certificate of Merit from the Philadelphia Classical Society. He attended Upper Montclair College High School and matriculated at Columbia University.
Professor Narrett graduated from Columbia in 1970 with a BA in Art History. He received his Masters degree with Honors in English and Comparative Literature in 1975 and his Ph.D in 1978 in these same disciplines all from Columbia University.
Professor Narrett’s dissertation on the Romantic poet, Percy Bysshe Shelley, The Comedic Vision of Shelley's Poetry, was written under the Columbia University scholar and professor, Karl Kroeber, who taught for nearly half a century in the English and comparative literature department. At the time his dissertation was completed, Professor Kroeber labelled Eugene Narrett as the greatest interpreter of Shelley extant.
Professor Narrett had a thirty plus year experience as a College teacher and was a published author in comparative literature, poetry, and art criticism. In 2010, Professor Narrett published in the English-American Association Journal, Identity, Theft, and Image Play in Coleridge. In 2010, Professor Narrett also authored a series of essays on Nietzsche and Schopenhauer and other western authors commenting on the nature of Western culture and how their views make use of or reflect on the relation of Judaism to the West.
In addition, Professor Narrett was an exhibiting artist (1977-92) and had gallery shows in New York City, Boston, Cambridge and Maynard Massachusetts and most recently and fatefully in Brattleboro, Vermont. He was also an accomplished self-taught flute player who once entertained strollers in the parks of Salzburg, Austria.
Professor Narrett taught, designed, created and directed many Liberal Arts courses and programs in fields including Art, Art History, History, Literature and Philosophy. His wide-ranging knowledge of history and his ability to integrate disciplines provided a comprehensive overview and rare insight into the most challenging conflicts and currents of our times. He published extensively on American politics and culture and on geopolitics and the Middle East. He is the author of three books: Gathered against Jerusalem: Essays on a False Peace; Israel Awakened: a Chronicle of the Oslo War; and Israel and the Endtimes: writings on the logic and surface turbulence of History (2006).
For much of his published work and radio guest appearances please see Israelendtimes.com as well as Amazon.com.
On language please see: http://www.webcommentary.com/php/ShowArticle.php?id=narrette&date=060924
As interpreter of Shakespeare please see: http://israelendtimes.com/blog/2010/08/28/thoughts-from-shakespeare.htm
Professor Narrett’s lifetime of scholarship and effort to find the essence in human behavior, as manifested in literature, art, and geo-politics came to a corporeal conclusion on a dark night in December but he always carried and forever will his soul carry the banner of learning and knowledge.
Professor Narrett was survived by his son, Gabriel Narrett and four younger brothers, David, Zachary, Seth and Matthew.
Intelligent Speculator is a market discussion and research group that focuses mainly on technology stocks and macroeconomic trades. Intelligent Speculator does provide new stock picks usually on a weekly basis that are either outright or long/short trades. Intelligent Speculator provides views of the different trends in the internet marketplace and its effects on the stocks involved. Since the author has both a financial (CFA exams completed) and a technology-based (through various experiences as webmaster/strategist) experience, he has an advantage in looking through the numbers. Visit Intelligent Speculator (http://www.intelligentspeculator.net/)
KLLJ is a private investor focusing on small cap stocks in biotechnology, emerging markets and renewable energy. I have been an active investor for 15 years and focus on picking stocks with tremendous upside. I enjoy sharing my thoughts in forums such as Seeking Alpha to help with my own due diligence process. I'm a critical thinker who appreciated constructive feedback to my investing ideas. I am not a short-term or momentum trader and like to think my strength is in picking good stocks with 10X potential returns. I don't believe in relying on Wall Street coverage of companies because of the inherent conflicts of interest (known or unknown.) We are in the market to make money and it is up to you, the individual retail investor to perform your own analysis for investment decisions if you want to win in the market. My analysis and viewpoints are not investment advice and you should always perform your own due diligence.
Avi Morris became interested in stocks while in high school when he started an investment club. It made him a few bucks and his interest in stocks continued. Over the years, Avi earned a portfolio between savings
Spencer Osborne is founder of Satellite Standard Group [SSG], and a partner of Sirius Buzz (http://siriusbuzz.com/). Sirius Buzz covers the satellite radio industry as well as companies that do business in this sector. Sirius Buzz provides information and opinion to readers with an interest in the sector from an investment, as well as consumer perspective.
Along with his work in the media sector, Spencer covers various equities that interest him and writes about these equities from a unique and "out of the box" perspective. Over the years Spencer has built a network of resources within the sectors he writes about. His opinion and insight is oft referred to and sought after by analysts.
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience, and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
Visit PropThink.com to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.
David Zanoni is ranked in the top 1% of blogging analysts on Tipranks.com for performance and accuracy. He focuses on growth & momentum stocks that are reasonably priced and likely to outperform the market over the long-term. David is a graduate of Rutgers University with a B.S. in Management. He is an independent long term investor of quality stocks and uses options for strategy. David believes in the power of innovation, capitalism, and the characteristics of the American spirit: intellect, fortitude, and adaptability to lead our country and the world to growing prosperity. His wants to help make people money by investing in high-quality growth stocks.
Bill Simoes is an independent researcher whose focus is applying his technical and financial expertise to energy stocks involved in exploration and production. Bill has an engineering degree, MBA and 35 years of experience in petroleum production, reserves estimation and properties evaluation. He worked for a number of large multi-national exploration and development companies before becoming president of a private oil and gas company. In these capacities he was involved in acquisitions, mergers and divestitures.
I am the Portfolio Manager for the RETIREE INCOME PORTFOLIO, DIVIDEND OVERDRIVE PORTFOLIO, and the OIL & GAS INCOME PORTFOLIO at PortfolioChannel.com. I am also the creator of the Cash Flow Retirement Replacement Ratio© used in retirement and investment planning. A Chartered Financial Analyst and Certified Financial Planner, I have spent over two decades managing high-net worth individual and institutional accounts, working as a portfolio manager and analyst. I have also had several stints working for a pair of Private Banks managing balanced, fixed income, and equity accounts.
I write about dividend growth stocks on my website www.dividendgrowthinvestor.com.
I am mostly a buyer of high quality dividend stocks, with solid competitive advantages. My holding period is forever, as long as the dividend is at least maintained. I tend to concentrate my efforts on stocks which grow earnings and dividends, which provides outstanding total returns over time. I only focus my attention to stocks with sustainable dividend payments. I am also a firm believer in diversification accross sectors and geographic locations.
I have been focusing my attention particularly to companies that regularly increase dividends to their shareholders on my website. On my blog I share my thoughts on investing in dividend paying stocks that have consistently increased their payments over time and tips on growing my dividend income. I hope that my blog will serve as an inspiration for my readers and that it would change their financial lives for the better.
Visit my website, Dividend Growth Investor (http://www.dividendgrowthinvestor.com/)
Apsara Biotech Research provides in-depth research on publicly traded stocks in the biotechnology sector. We pride ourselves on conducting high quality research for our clients and the public markets. Apsara is not affiliated with a broker-dealer and does not underwrite public offerings or provide investment banking services to the companies that it researches. Therefore, the research coverage provided in our reports are not influenced by the prospect of future investment banking and underwriting fee revenue.
Instead, Apsara and its contributors hold long and short positions in the stocks that we write about. Our research commentary is supported by our genuine opinions about the securities covered, rather than a motivation to derive future fee revenue from the subject companies.
We hope that you find our approach to biotechnology sector research refreshing, original and accurate.
Our research director is Yang Yu and can be reached at firstname.lastname@example.org
Editor for The Biotech Forum (www.biotechforumsa.com), the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade. For Free weekly investment reports on small, attractive biotech stocks just register at www.bretjenseninvests.com
Bob is retired from a career in law enforcement including more than 20 years as an instructor of Investigative Interviewing. He is a Dividend Growth investor using dividend yield from low beta stocks for income and preservation of capital. Bob has self managed his portfolio since early in 2011. He hopes to encourage discussion among those already in retirement and receiving income from their portfolios.
My curent portfolio is available here:
I believe that everyone needs a portfolio business plan.
Here's a copy of ours:: http://seekingalpha.com/article/2426965-our-retirement-portfolio-business-plan-legacy-edition-part-two
A list of Dividend Growth Safety Superstars for the past decade is available here: http://seekingalpha.com/article/2255863-a-review-of-the-dividend-safety-superstars
I have a MBA in Healthcare Administration and Finance, a BS in Pharmacy, and a Doctorate degree in Pharmacy/Medicine. Investing in Biotechnology companies is my passion and I am also currently actively working in a teaching hospital. Also previously worked in the Pharmaceutical industry in regulatory affairs. My investment philosophy is investing in companies that you are familiar with and like to use their products and services. Because if you like it so will everyone else. Over 20 years of investment experience mostly in the healthcare.
I spend most of my time reading through annual reports looking for a small-cap stock to feature in my monthly edition of "The Conservative Investor Digest." That is where you can find my best work, and that is where I focus my research. You can become a subscriber here: https://gumroad.com/l/HmqJx